# Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial

> **NCT05686538** · PHASE2,PHASE3 · RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 80 (estimated)

## Conditions studied

- AML/MDS

## Interventions

- **OTHER:** iDLI

## Key facts

- **NCT ID:** NCT05686538
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2028-01
- **Final completion:** 2030-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686538, "Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05686538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*